Why cure, why now?

被引:13
|
作者
Kuritzkes, Daniel R. [1 ,2 ]
机构
[1] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02139 USA
[2] Harvard Med Sch, Boston, MA USA
关键词
HIV-INFECTED PATIENTS; HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; LATENT RESERVOIR; T-CELLS; INTERRUPTION; CCR5; ANTI-PD-1; SAFETY; PANOBINOSTAT;
D O I
10.1136/medethics-2015-103113
中图分类号
B82 [伦理学(道德学)];
学科分类号
摘要
Combination antiretroviral therapy (cART) is highly effective at preventing morbidity and mortality due to infection with human immunodeficiency virus (HIV), but does not eradicate the virus. Consequently, cART must be administered life-long. Recent progress has stimulated research towards a cure of HIV infection. Approaches under investigation include hematopoietic stem cell transplantation, latency reactivating agents, immune based therapies, and cell-based therapies. Each of these approaches carries potential risks that must be weighed against the availability of safe and effective cART. Balancing the risks and benefits of this research poses unique challenges to potential study participants, clinicians and investigators.
引用
收藏
页码:67 / 70
页数:4
相关论文
共 50 条
  • [1] Why Now? Why Not?
    Warnecke, Lauren
    [J]. DANCE MAGAZINE, 2021, 95 (08): : 14 - 15
  • [2] Why Us? Why Now?
    Mclellan, Julia
    Benger, Tess
    [J]. CANADIAN THEATRE REVIEW, 2023, 194 : 47 - 50
  • [3] Why SGML? Why now?
    Marcoux, Y
    Sevigny, M
    [J]. JOURNAL OF THE AMERICAN SOCIETY FOR INFORMATION SCIENCE, 1997, 48 (07): : 584 - 592
  • [4] Why ISO? Why now?
    DiNitto, JR
    [J]. TRANSFUSION, 1998, 38 (01) : 5 - 8
  • [5] WHY MARS? WHY NOW?
    Hassler, Susan
    [J]. IEEE SPECTRUM, 2009, 46 (06) : 26 - 29
  • [6] WHY INDIA? WHY NOW?
    O'Driscoll, Mike
    [J]. AMERICAN CERAMIC SOCIETY BULLETIN, 2019, 98 (09): : 48 - 49
  • [7] Why Cuba? Why now?
    Pietroni, Patrick
    [J]. INTERNATIONAL JOURNAL OF CUBAN STUDIES, 2008, 1 (01) : 6 - 11
  • [8] Why pharmacogenomics? Why now?
    David Housman
    Fred D. Ledley
    [J]. Nature Biotechnology, 1998, 16 : 492 - 493
  • [9] Why pharmacogenomics? Why now?
    Housman, D
    Ledley, FD
    [J]. NATURE BIOTECHNOLOGY, 1998, 16 (06) : 492 - 493
  • [10] WHY CBE AND WHY NOW
    RIDLEY, WJ
    [J]. URBAN LAWYER, 1982, 14 (03): : 563 - 580